Depo-Provera contraceptive may increase risk of cardiovascular disease

doi:10.1136/bmj.325.7363.513

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ research articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Xavier Bosch

Barcelona

The long acting contraceptive Depo-Provera (depot medroxyprogesterone acetate, DMPA) may increase the risk of heart disease in women taking the drug for more than a year, new research has suggested.

The study, due to be published on 17 September in Circulation, the journal of the American Heart Association, and already available on line (www.circ.ahajournals.org/), shows that the contraceptive can impair arterial responsiveness to increased blood flow as a result of endothelial cell abnormality.

Lead author Professor Dudley Pennell of the Royal Brompton Hospital, London, …